Literature DB >> 7112121

Quantitative autoradiographic mapping of herpes simplex virus encephalitis with a radiolabeled antiviral drug.

Y Saito, R W Price, D A Rottenberg, J J Fox, T L Su, K A Watanabe, F S Philips.   

Abstract

2'-Fluoro-5-methyl-l-beta-D-arabinosyluracil (FMAU) labeled with carbon-14 was used to image herpes simplex virus type 1-infected regions of rat brain by quantitative autoradiography. FMAU is a potent antiviral pyrimidine nucleoside which is selectively phosphorylated by virus-coded thymidine kinase. When the labeled FMAU was administered 6 hours before the rats were killed, the selective uptake and concentration of the drug and its metabolites by infected cells (defined by immunoperoxidase staining of viral antigens) allowed quantitative definition and mapping of HSV-1-infected structures in autoradiograms of brain sections. These results show that quantitative autoradiography can be used to characterize the local metabolism of antiviral drugs by infected cells in vivo. They also suggest that the selective uptake of drugs that exploit viral thymidine kinase for their antiviral effect can, by appropriate labeling, be used in conjunction with clinical neuroimaging techniques to define infected regions of human brain, thereby providing a new approach to the diagnosis of herpes encephalitis in man.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7112121     DOI: 10.1126/science.7112121

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  12 in total

Review 1.  Imaging transgene expression with radionuclide imaging technologies.

Authors:  S S Gambhir; H R Herschman; S R Cherry; J R Barrio; N Satyamurthy; T Toyokuni; M E Phelps; S M Larson; J Balatoni; R Finn; M Sadelain; J Tjuvajev; R Blasberg
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Imaging gene expression: principles and assays.

Authors:  S S Gambhir; J R Barrio; H R Herschman; M E Phelps
Journal:  J Nucl Cardiol       Date:  1999 Mar-Apr       Impact factor: 5.952

Review 3.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Breast Cancer Treatment in the Era of Molecular Imaging.

Authors:  Gundula Edelhauser; Martin Funovics
Journal:  Breast Care (Basel)       Date:  2008-12-17       Impact factor: 2.860

5.  Specific neuro-radiological diagnosis of herpes encephalitis in an animal model.

Authors:  G M Cleator; P E Klapper; A G Lewis; H L Sharma; M Longson
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

6.  HM-PAO-imaging and herpes encephalitis.

Authors:  G M Cleator; A G Lewis; P E Klapper; H L Sharma; A M Smith
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir.

Authors:  Win-Ping Deng; Wen K Yang; Wen-Fu Lai; Ren-Shyan Liu; Jeng-Jong Hwang; Den-Mei Yang; Ying-Kai Fu; Hsin-Ell Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

Review 8.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

Review 9.  Noninvasive molecular imaging of neuroinflammation.

Authors:  Andreas H Jacobs; Bertrand Tavitian
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-02       Impact factor: 6.200

Review 10.  The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies.

Authors:  Alan R Penheiter; Stephen J Russell; Stephanie K Carlson
Journal:  Curr Gene Ther       Date:  2012-02-01       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.